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Spatially and temporally resolved in situ monitoring of biochemical cell culture environments, e.g., in application 
to therapeutic cell bioreactors, is of critical importance for facilitating the development of new and reliable quality 
control methodologies for cell therapies. Identifying and monitoring secreted biomolecular critical quality 
attributes (CQAs) to enable online feedback control will enable large scale, cost-effective manufacturing of 
therapeutic cells. These CQA biomarkers have varying concentrations within a bioreactor, both in time and 
space. Current methods for monitoring these diverse biomolecules are generally ex-situ, time consuming, 
destructive, provide bulk measurements, or lack the ability to reveal the complete secretome/metabolome 
composition. The Dynamic Mass Spectrometry Probe (DMSP) synergistically incorporates a sampling interface 
for localized intake of a small fluid volume of the cellular content, a micro-fabricated mass exchanger for sample 
conditioning and inline separation, and an integrated electrospray ionization (ESI)  emitter for softly ionizing (i.e. 
preserved biochemical structure) extracted biomolecules for mass spectrometry (MS). ESI-MS via DMSP 
treatment enables both biomarker discovery and transient (~1 min) analysis of biochemical information 
indicative of cell health and potency. DMSP is manufactured using advanced batch microfabrication techniques, 
which minimize dead volume (~20 nL) and ensure repeatable operation and precise geometry of each device. 
DMSP treatment removes 99% of compounds that interfere with mass spectrometry analysis, such as inorganic 
salts, while retaining biomolecules of interest within the sample for ESI-MS analysis. DMSP has demonstrated 
the ability to substantially increase signal to noise ratio in MS detection of biomolecules, and to further enhance 
sensitivity for probing lower 
biomarker concentrations via 
introduction of ESI-MS 
enhancing molecules (i.e. proton 
donating chemicals, protein 
denaturing solvents, and 
supercharging agents) into the 
sample within the integrated 
mass exchanger. To exemplify 
the DMSP’s unique capabilities, 
Fig. 1 demonstrates detection of 
multiple low-concentration 
protein biomarkers sampled 
from a biochemically-complex 
cell media solution serving as a 
proxy to samples taken directly 
from cell growth bioreactors [1].  
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Figure 1 - Mass spectra produced via direct infusion ESI-MS through 
DMSP A. Untreated 1xPBS with 5 uM cytochrome-c (12 kDa), 5 µM IL-
6 (21 kDa), and 5 µM IL-8 (8.4 kDa) shows no identifiable peaks 
associated with protonation of biomolecules. B. 1% AA treatment 
reveals multiple charge states associated with IL-6 only. C. 1% AA 2% 
m-NBA treatment reveals fully protonated charge states of cytochrome-
c and IL-6. 
